Menu
Search
|

Menu

Close
X

CareDx Inc CDNA.OQ (NASDAQ Stock Exchange Global Market)

5.57 USD
-0.14 (-2.45%)
As of 2:29 AM IST
chart
Previous Close 5.71
Open 5.69
Volume 17,410
3m Avg Volume 57,568
Today’s High 5.82
Today’s Low 5.51
52 Week High 7.98
52 Week Low 0.76
Shares Outstanding (mil) 22.54
Market Capitalization (mil) 126.68
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY17
36
FY16
41
FY15
28
EPS (USD)
FY17
-1.079
FY16
-2.510
FY15
-1.155
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
2.70
5.77
Price to Book (MRQ)
vs sector
10.18
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
286.45
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-68.64
14.43
Return on Equity (TTM)
vs sector
-131.60
16.13

EXECUTIVE LEADERSHIP

Michael Goldberg
Independent Chairman of the Board, Since 2011
Salary: --
Bonus: --
Peter Maag
President, Chief Executive Officer, Director, Since 2012
Salary: $370,735.00
Bonus: $176,904.00
Michael Bell
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Mitchell Nelles
Chief Operating Officer, Since 2012
Salary: --
Bonus: --
John Sninsky
Chief Scientific Officer, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

3260 Bayshore Blvd
BRISBANE   CA   94005-1021

Phone: +1415.2872300

CareDx, Inc. is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company's commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. Its products under development for transplant monitoring include AlloSure, a development-stage transplant surveillance solution, which applies next generation sequencing to detect and quantitate genetic differences between donor-derived cell-free deoxyribonucleic acid (dd-cfDNA) in the blood stream emanating from the donor heart. It offers the AlloMap Score Variability service, which provides complementary information to help personalize long-term care of heart transplant recipients.

SPONSORED STORIES